Relmada Therapeutics said Wednesday morning that a Phase 3 study testing its major depression drug, REL-1017, is likely to fail, cratering its stock price.

The race to create the next best medication for obesity is well underway, and the incumbents are doing everything they can to shore up manufacturing, fight the compounders and develop ...

End­points 11 win­ner As­cid­i­an Ther­a­peu­tics: A search-and-re­place tech­nol­o­gy comes to RNA ...

A Q&A with a No­bel Prize win­ner; Pfiz­er meets with Star­board; J&J re­ports Q3 earn­ings; and more ...

Septerna is joining biotech's IPO on-deck circle, preparing for a public offering with two other startups that have similar ambitions. It announced its plans in a securities filing Wednesday ...

The European Medicines Agency will meet on Thursday to discuss Oxbryta — the sickle cell treatment Pfizer inherited in its $5.4 billion acquisition of Global Blood Therapeutics ...

The FDA has approved Johnson & Johnson’s IL-23 blocker Tremfya to treat ulcerative colitis, a boost to the pharma’s hopes that the drug will serve as a worthy follow-up to ...

BioMarin is bringing prominent dealmaker James Sabry onto its executive team, along with Amgen rare disease veteran Greg Friberg. Sabry will start on Oct. 7 as chief business officer, following ...

GSK is handing mRNA vaccine partner CureVac €400 million ($429 million) upfront to take over full rights to the influenza and Covid vaccine candidates they have been collaborating on, while ...

#AS­CO24: A roundup of the lat­est da­ta from Merus, Mor­phoSys and oth­ers ...

To help meet the heightened demand for its injectable products, Eli Lilly is acquiring a facility from Nexus Pharmaceuticals, with production anticipated to start at the end of next year ...

(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Teladoc Health's CEO Jason Gorevic is stepping down ...